Zealand Pharma A/S Stock price

Equities

ZEAL

DK0060257814

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen 10:59:51 2024-02-23 EST 5-day change 1st Jan Change
478 DKK +1.10% Intraday chart for Zealand Pharma A/S -1.40% +28.08%

Financials

Sales 2023 * 347M 50.37M 67.94M Sales 2024 * 1.4B 203M 274M Capitalization 29.38B 4.27B 5.76B
Net income 2023 * -556M -80.74M -109M Net income 2024 * 186M 27.01M 36.44M EV / Sales 2023 * 79.7 x
Net cash position 2023 * 1.75B 254M 343M Net cash position 2024 * 3.2B 465M 627M EV / Sales 2024 * 18.7 x
P/E ratio 2023 *
-36.9 x
P/E ratio 2024 *
320 x
Employees 249
Yield 2023 *
-
Yield 2024 *
-
Free-Float 93.22%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.27%
1 week-1.40%
Current month+1.23%
1 month+6.60%
3 months+46.63%
6 months+78.09%
Current year+28.08%
More quotes
1 week
457.60
Extreme 457.6
496.00
1 month
431.00
Extreme 431
505.50
Current year
342.20
Extreme 342.2
505.50
1 year
205.60
Extreme 205.6
505.50
3 years
69.55
Extreme 69.55
505.50
5 years
69.55
Extreme 69.55
505.50
10 years
58.00
Extreme 58
505.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 09-12-31
Director of Finance/CFO - 22-10-31
Chief Tech/Sci/R&D Officer - 20-09-03
Members of the board TitleAgeSince
Director/Board Member 66 19-04-03
Chairman 69 14-12-31
Director/Board Member 68 18-04-18
More insiders
Date Price Change Volume
24-02-23 478 +1.10% 176 285
24-02-22 472.8 +2.43% 349,608
24-02-21 461.6 -5.14% 528,743
24-02-20 486.6 +1.04% 380,556
24-02-19 481.6 -0.66% 160,897

Delayed Quote Nasdaq Copenhagen, February 23, 2024 at 10:59 am

More quotes
Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The Company operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
472.8 DKK
Average target price
459.2 DKK
Spread / Average Target
-2.88%
Consensus
1st Jan change Capi.
+28.08% 4 262 M $
+5.90% 110 B $
+11.21% 104 B $
+9.93% 23 902 M $
-10.70% 22 243 M $
-26.36% 21 573 M $
-6.59% 18 925 M $
-13.78% 16 036 M $
+1.61% 13 271 M $
+42.04% 12 608 M $
Bio Therapeutic Drugs
  1. Stock
  2. Equities
  3. Stock Zealand Pharma A/S - Nasdaq Copenhagen
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer